Stakeholders seek to reshape FDA’s guidance for master protocols
Regulatory NewsEmily Hayes
Biologics/ biosimilars/ vaccinesClinical TrialsPharmaceuticalsUnited StatesRegulatory NewsEmily HayesBiologics/ biosimilars/ vaccinesClinical TrialsPharmaceuticalsUnited States